About My Guest:
Dr. Connie Westhoff directs the Laboratory for Immunohematology and Genomics at the New York Blood Center. She is an adjunct Assistant Professor in the Department of Transfusion Medicine at the University of Pennsylvania. She lectures nationally and internationally, and she has published more than 80 scientific papers and numerous book chapters. Dr. Westhoff is an Associate Editor for the Immunohematology and Genomics Section of the AABB journal “Transfusion,” and she’s also an editor of my favorite blood banking textbook, the AABB Technical Manual. Finally, Connie is actually an original inductee to the National Blood Foundation Hall of Fame.
DISCLAIMER: The opinions expressed on this episode are those of my guest and I alone, and do not reflect those of the organizations with which either of us is affiliated. Neither Dr. Westhoff nor I have any relevant financial disclosures.
The images below are generously provided by Dr. Westhoff.
- 1:52: Intro to Dr. Westhoff
- 3:38: Dr. Westhoff’s background
- 5:55: Basic testing for RhD
- 9:38: “D” vs. “RhD” vs. “RHD”
- 10:46: Why is D testing different from that for K or Jka?
- 13:28: What’s an epitope?
- 16:42: “Weak D” vs. “Partial D”
- 24:56: How practice differs between hospitals with D testing
- 28:00: Practice recommendation for pregnant females with weak D
- 32:57: Practice recommendation for weak D transfusion recipients
- 37:01: Proportion of serologic weak D that are types 1, 2, or 3
- 39:37: Cost and turnaround time
- Sandler SG et al. It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype. Transfusion 2015;55:680–689.
- Kacker S et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype. Transfusion 2015;55;2095–2103.